-

Eurofins Environment Testing Launches PFAS Exposure Self-Collection Blood Test

LUXEMBOURG--(BUSINESS WIRE)--Per- and Polyfluorinated Alkyl Substances (PFAS), such as PFOA and PFOS, known as “forever chemicals”, characteristically resist natural breakdown in the environment and human bodies. The US Centers for Disease Control and Prevention (CDC) reports that exposure to these chemicals may cause adverse health effects.

In a leap forward for PFAS identification through blood testing, Eurofins (Paris:ERF) Environment Testing and its research partners have developed a self-administered sampling kit, PFAS Exposure™. The kit is the first of its kind and uses a simple finger prick. To date, testing for PFAS in blood has relied on serum as an estimation for whole blood and required a blood draw conducted by a healthcare practitioner.

Knowledge of PFAS levels in blood can assist in understanding PFAS exposure from one’s occupation, food, drinking water, indoor air, and consumer products such as cookware and clothing and the environmental effects this has on humans.

Eurofins’ PFAS Exposure™ collection kits are an all-in-one solution that include the essentials for collection and transport, allowing participants to self-collect samples at home or work, and submit them directly to the laboratory.

The PFAS Exposure kit is available through Eurofins’ at-home health testing business, empowerDX. Kits can be purchased online for $399 and are shipped directly to the customers home or business.

Increasing knowledge of PFAS in blood

Eurofins will provide data for 47 PFAS compounds in whole blood, expanding on the CDC National Health and Nutrition Examination Survey (NHANES) study and database where 16 PFAS compounds in serum are reported.

Further information: www.EurofinsPFAS.com

About Eurofins Environment Testing America

The Eurofins Environment Testing network in the US contributes to a clean and safe environment by providing market-leading laboratory testing, monitoring, and consulting services to a wide range of industrial companies, environmental consultants, contractors, retailers and government authorities.

About empowerDX

empowerDX is the online shop for easy at-home health testing. empowerDX specializes in FDA-authorized COVID-19 testing, women’s health, men’s health, sexual health and general wellness testing. empowerDX is positioned to lead the market for cutting edge, self-collected diagnostic and non-diagnostic testing.

To learn more: empowerdxlab.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Brian Williams
ir@eurofins.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

Brian Williams
ir@eurofins.com

More News From Eurofins

Eurofins: Weekly Report on Share Repurchases From 20th July to 24th July 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 20/07/2026 FR0014000MR3 3 180 70.8332 CEUX EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 20/07/2026 FR0014000MR3 6 820 70.7743 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 21/07/...

Eurofins Makes Significant Progress in H1 2026 Towards Its Mid-Term 2027 Objectives, With 130bps of Adjusted EBITDA Margin Expansion, Strong Cash Conversion, and 29% EPS Growth

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Financial highlights in H1 2026 Basic EPS8 grew 29% to €1.55 in H1 2026 vs €1.20 in H1 2025, as Eurofins continued to accumulate the operational benefits from the five-year investment programme in its hub and spoke network of laboratories and digitalisation initiatives. Revenues of €3,701m increased by 2.5% as reported including a 2.9% headwind from foreign currency, and 2.7% organically13. Organic growth13 improved as the half...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 13th July to 17th July 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Weekly report on share repurchases from 13th July to 17th July 2026   Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/07/2026 FR0014000MR3 15 000 69.1984 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 13/07...
Back to Newsroom